Global Cancer Supportive Care Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Therapeutic Class;

Granulocyte Colony Stimulating Factors - Chemotherapy Induced Neutropenia (CIN), Erythropoietin Stimulating Agents (ESAs) For Chemotherapy Induced Anemia (CIA), Anti-emetics For Chemotherapy Induced Nausea and Vomiting (CINV), Bisphosphonates For Cancer Induced Bone Diseases & Opioids, and NSAIDs For Cancer Pain.

By Application;

Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, and Others.

By Distribution Channel;

Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Providers.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn319187072 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Cancer Supportive Care Drugs Market (USD Million), 2021 - 2031

In the year 2024, the Global Cancer Supportive Care Drugs Market was valued at USD 12,107.24 million. The size of this market is expected to increase to USD 15,508.28 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.6%.

The global cancer supportive care drugs market is witnessing significant growth, driven by a multitude of factors shaping the healthcare landscape. Cancer incidence rates continue to rise globally, creating an escalating demand for supportive care drugs that alleviate the adverse effects of cancer treatments. These drugs play a crucial role in managing symptoms such as pain, nausea, fatigue, and anemia, thereby improving patients' quality of life during their cancer journey.

Advancements in medical research and technology have led to the development of novel cancer therapies, including targeted therapies and immunotherapies, which often come with their own set of side effects. This further fuels the demand for supportive care drugs to manage these adverse events effectively. Additionally, the increasing prevalence of chronic diseases, aging population, and growing awareness about cancer care are contributing to the expansion of the supportive care drugs market globally.

The pandemic has underscored the importance of supportive care in cancer treatment, as cancer patients are considered vulnerable to severe complications from the virus. The pandemic has prompted healthcare providers to prioritize supportive care interventions to ensure the continuity of cancer treatment while minimizing the risk of infection. As a result, the market for cancer supportive care drugs is expected to witness sustained growth in the coming years as healthcare systems worldwide focus on improving patient outcomes and quality of life throughout the cancer care continuum.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Therapeutic Class
    2. Market Snapshot, By Application
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Cancer Supportive Care Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing cancer prevalence worldwide
        2. Advancements in cancer treatment
        3. Growing awareness and access to healthcare
        4. Aging population
      2. Restraints
        1. High treatment costs
        2. Stringent regulatory requirements
        3. Adverse effects of supportive care drugs
        4. Limited access to healthcare in developing regions
      3. Opportunities
        1. Development of novel supportive care drugs
        2. Expansion in emerging markets
        3. Collaborations and partnerships
        4. Personalized medicine approach
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Cancer Supportive Care Drugs Market, By Therapeutic Class, 2021 - 2031 (USD Million)
      1. Granulocyte Colony Stimulating Factors
        1. Chemotherapy Induced Neutropenia (CIN)
        2. Erythropoietin Stimulating Agents (ESAs) for Chemotherapy Induced Anemia (CIA)
        3. Anti-emetics for Chemotherapy Induced Nausea and Vomiting (CINV)
        4. Bisphosphonates for Cancer Induced Bone Diseases
        5. Opioids
        6. NSAIDs for Cancer Pain
    2. Global Cancer Supportive Care Drugs Market, By Application, 2021 - 2031 (USD Million)
      1. Breast Cancer
      2. Lung Cancer
      3. Colorectal Cancer
      4. Prostate Cancer
      5. Liver Cancer
      6. Stomach Cancer
      7. Others
    3. Global Cancer Supportive Care Drugs Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online Providers
    4. Global Cancer Supportive Care Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Amgen Inc
      2. Merck & Co., Inc
      3. F. Hoffmann-La Roche Ltd
      4. Novartis AG
      5. Pfizer Inc
      6. Bayer AG
      7. Johnson & Johnson
      8. Takeda Pharmaceutical Company Limited
      9. Teva Pharmaceutical Industries Ltd
      10. Bristol Myers Squibb Company
  7. Analyst Views
  8. Future Outlook of the Market